Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea

详细信息    查看全文

• 作者：Tamarah Koleala ; Stephan Karl ; Moses Laman ; Brioni R Moore…
• 关键词：Malaria ; Plasmodium falciparum ; in vitro drug susceptibility ; Resistance mutations
• 刊名：Malaria Journal
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：14
• 期：1
• 全文大小：828 KB
• 参考文献：1. Saint-Yves IF. The alleged resistance of / Plasmodium falciparum to chloroquine in the Milne Bay District. P N G Med J. 1971;14:77-.
  2. al-Yaman F, Genton B, Mokela D, Narara A, Raiko A, Alpers MP. Resistance of / Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990-993. P N G Med J. 1996;39:16-2.
  3. Casey GJ, Ginny M, Uranoli M, Mueller I, Reeder JC, Genton B, et al. Molecular analysis of / Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. Am J Trop Med Hyg. 2004;70:251-.
  4. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359:2545-7. CrossRef
  5. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006.
  6. Papua New Guinea Department of Health. National Malaria Treatment Protocol. 7th ed. Port Moresby: Government of Papua New Guinea; 2009.
  7. Benjamin J, Moore B, Lee ST, Senn M, Griffin S, Lautu D, et al. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob Agents Chemother. 2012;56:2465-1. CrossRef
  8. Wongsrichanalai C, Sibley CH. Fighting drug-resistant / Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect. 2013;19:908-6. CrossRef
  9. Noedl H, Wongsrichanalai C, Wernsdorfer WH. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 2003;19:175-1. CrossRef
  10. Quashie N, de Koning H, Ranford-Cartwright L. An improved and highly sensitive microfluorimetric method for assessing susceptibility of / Plasmodium falciparum to antimalarial drugs / in vitro. Malar J. 2006;5:95. CrossRef
  11. Smilkstein M, Sriwilaijaroen N, Kelly J, Wilairat P, Riscoe M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother. 2004;48:1803-. CrossRef
  12. Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 2011;585:1551-2. CrossRef
  13. Wong RP, Lautu D, Tavul L, Hackett SL, Siba P, Karunajeewa HA, et al. / In vitro sensitivity of / Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea. Trop Med Int Health. 2010;15:342-. CrossRef
  14. Wong RP, Karunajeewa H, Mueller I, Siba P, Zimmerman PA, Davis TM. Molecular assessment of / Plasmodium falciparum resistance to antimalarial drugs in Papua New Guinea using an extended ligase detection reaction fluorescent microsphere assay. Antimicrob Agents Chemother. 2011;55:798-05. CrossRef
  15. Laman M, Moore BR, Benjamin JM, Yadi G, Bona C, Warrel J, et al. Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: An open-label randomized trial. PLoS Med. 2014;11:e100177. CrossRef
  16. Karl S, Wong RP, St Pierre TG, Davis TM. A comparative study of a flow-cytometry-based assessment of / in vitro Plasmodium falciparum drug sensitivity. Malar J. 2009;8:294. CrossRef
  17. Karl S, Davis TME, St Pierre TG. Parameterization of high magnetic field gradient fractionation columns for applications with / Plasmodium falciparum infected human erythrocytes. Malar J. 2010;9:116. CrossRef
  18. Trager W, Jensen JB. Human malaria parasites in continuous culture
• 刊物主题：Parasitology; Infectious Diseases; Tropical Medicine;
• 出版者：BioMed Central
• ISSN：1475-2875

文摘

Background In northern Papua New Guinea (PNG), most Plasmodium falciparum isolates proved resistant to chloroquine (CQ) in vitro between 2005 and 2007, and there was near-fixation of pfcrt K76T, pfdhfr C59R/S108N and pfmdr1 N86Y. To determine whether the subsequent introduction of artemisinin combination therapy (ACT) and reduced CQ-sulphadoxine-pyrimethamine pressure had attenuated parasite drug susceptibility and resistance-associated mutations, these parameters were re-assessed between 2011 and 2013. Methods A validated fluorescence-based assay was used to assess growth inhibition of 52 P. falciparum isolates from children in a clinical trial in Madang Province. Responses to CQ, lumefantrine, piperaquine, naphthoquine, pyronaridine, artesunate, dihydroartemisinin, artemether were assessed. Molecular resistance markers were detected using a multiplex PCR ligase detection reaction fluorescent microsphere assay. Results CQ resistance (in vitro concentration required for 50% parasite growth inhibition (IC50) >100 nM) was present in 19% of isolates. All piperaquine and naphthoquine IC50s were 50s showed three groupings (lumefantrine; CQ, piperaquine, naphthoquine; pyronaridine, dihydroartemisinin, artemether, artesunate). Most isolates (96%) were monoclonal pfcrt K76T (SVMNT) mutants and most (86%) contained pfmdr1 N86Y (YYSND). No wild-type pfdhfr was found but most isolates contained wild-type (SAKAA) pfdhps. Compared with 2005-007, the geometric mean (95% CI) CQ IC50 was lower (87 (71-07) vs 167 (141-97) nM) and there had been no change in the prevalence of pfcrt K76T or pfmdr1 mutations. There were fewer isolates of the pfdhps (SAKAA) wild-type (60 vs 100%) and pfdhfr mutations persisted. Conclusions Reflecting less drug pressure, in vitro CQ sensitivity appears to be improving in Madang Province despite continued near-fixation of pfcrt K76T and pfmdr1 mutations. Temporal changes in IC50s for other anti-malarial drugs were inconsistent but susceptibility was preserved. Retention or increases in pfdhfr and pfdhps mutations reflect continued use of sulphadoxine-pyrimethamine in the study area including through paediatric intermittent preventive treatment. The susceptibility of local isolates to lumefantrine may be unrelated to those of other ACT partner drugs. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12610000913077.